Pham Quang X sold $17K of CVKD
Pham Quang X (CEO and Chairman) sold 3,298 shares of Cadrenal Therapeutics, Inc. (CVKD) at $5.28 on 2026-05-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates insider transaction records; without accompanying company news, it is unlikely to change fundamental valuation expectations on its own.
Market read
Traders may monitor for patterns in insider activity, but this specific sale is not a standalone fundamental catalyst.
What to watch
The filing date may drive short-lived attention, but the economic meaning is constrained by the pre-arranged nature and modest dollar size.
Background
SEC Form 4 discloses an insider open-market sale by the issuer’s CEO/Chairman and 10% owner, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
CEO/Chairman Pham Quang X sold 3,298 shares of Cadrenal Therapeutics (CVKD) for ~$17.4K under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any reaction is more about sentiment than fundamentals.
Form 4 provides a concrete transaction datapoint, but the 10b5-1 pre-arrangement typically dampens interpretive value for near-term price moves.
Market effects
Minimal; this is company-specific insider activity without any stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale was under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the insider transaction disclosure (CVKD).
- insiderPham Quang X
CEO and Chairman; sold 3,298 shares at $5.2800/share under a 10b5-1 plan.
